NCT05703854View on ClinicalTrials.gov

Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 29, 2023

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Advanced Renal Cell CarcinomaAdvanced MesotheliomaAdvanced Osteosarcoma
Interventions
DRUG

CAR.70/IL15-transduced CB-derived NK cells

Given by IV (vein)

DRUG

Fludarabine phosphate

Given by IV (vein)

DRUG

Cyclophosphamide

Given by IV (vein)

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER